The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing

[1]  K. Hoang-Xuan,et al.  Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.

[2]  D. Gilbert,et al.  Complex correlations: replication timing and mutational landscapes during cancer and genome evolution. , 2014, Current opinion in genetics & development.

[3]  R. Siebert,et al.  Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice , 2014, Acta Neuropathologica.

[4]  M. Montesinos-Rongen,et al.  Differential effects of CXCR4‐CXCL12‐ and CXCR7‐CXCL12‐mediated immune reactions on murine P0106–125‐induced experimental autoimmune neuritis , 2013, Neuropathology and applied neurobiology.

[5]  W. Klapper,et al.  Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas , 2013, Acta Neuropathologica.

[6]  Emmanuel Barillot,et al.  Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis , 2013, PloS one.

[7]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[8]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[9]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[10]  M. Gelabert-González,et al.  Primary central nervous system lymphoma. , 2013, Neurologia.

[11]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[12]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[13]  R. Siebert,et al.  Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma , 2012, Acta Neuropathologica.

[14]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Fukushi,et al.  Teneurin-4 Is a Novel Regulator of Oligodendrocyte Differentiation and Myelination of Small-Diameter Axons in the CNS , 2012, The Journal of Neuroscience.

[16]  K. Hoang-Xuan,et al.  Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.

[17]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[18]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[19]  W. Klapper,et al.  Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma , 2011, Leukemia.

[20]  R. Siebert,et al.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma , 2011, Acta Neuropathologica.

[21]  Manuel A. R. Ferreira,et al.  Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4 , 2011, Nature Genetics.

[22]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[23]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[24]  B. O'neill,et al.  Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens , 2011, Clinical Cancer Research.

[25]  K. Karube,et al.  Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. , 2011, Blood.

[26]  Dereje D. Jima,et al.  Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. , 2010, Blood.

[27]  Daniela Kenzelmann-Broz,et al.  The expression of teneurin-4 in the avian embryo: potential roles in patterning of the limb and nervous system. , 2010, The International journal of developmental biology.

[28]  Aris Floratos,et al.  geWorkbench: an open source platform for integrative genomics , 2010, Bioinform..

[29]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[30]  R. Siebert,et al.  Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma , 2010, Acta Neuropathologica.

[31]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[32]  Michael O Dorschner,et al.  Sequencing newly replicated DNA reveals widespread plasticity in human replication timing , 2009, Proceedings of the National Academy of Sciences.

[33]  A. Mottok,et al.  Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. , 2009, Blood.

[34]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[35]  R. Siebert,et al.  Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma , 2009, Leukemia.

[36]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[37]  A. Chott,et al.  Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3 , 2008, Clinical Cancer Research.

[38]  B. O'neill,et al.  Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Rosenwald,et al.  Genomic alterations and gene expression in primary diffuse large B‐cell lymphomas of immune‐privileged sites: the importance of apoptosis and immunomodulatory pathways , 2008, The Journal of pathology.

[40]  W. Klapper,et al.  Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma , 2008, Journal of neuropathology and experimental neurology.

[41]  P. Park,et al.  Pathway analysis of primary central nervous system lymphoma. , 2008, Blood.

[42]  R. Spang,et al.  Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell , 2008, Leukemia.

[43]  G. Reifenberger,et al.  Transcriptional Profiling of the Nuclear Factor-&kgr;B Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression , 2007, Journal of neuropathology and experimental neurology.

[44]  A. Rosenwald,et al.  Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma , 2006, Clinical Cancer Research.

[45]  J. Fridlyand,et al.  Gene expression and angiotropism in primary CNS lymphoma. , 2006, Blood.

[46]  G. Reifenberger,et al.  Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. , 2005, The American journal of pathology.

[47]  C. Schaller,et al.  Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. , 2004, Blood.

[48]  R. Siebert,et al.  Molecular Characterization of BCL6 Breakpoints in Primary Diffuse Large B‐cell Lymphomas of the Central Nervous System Identifies GAPD as Novel Translocation Partner , 2003, Brain pathology.

[49]  S. Minoshima,et al.  A novel giant gene CSMD3 encoding a protein with CUB and sushi multiple domains: a candidate gene for benign adult familial myoclonic epilepsy on human chromosome 8q23.3-q24.1. , 2003, Biochemical and biophysical research communications.

[50]  Ed Schuuring,et al.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma , 2003, Immunogenetics.

[51]  R. Siebert,et al.  Interphase Cytogenetic Analysis of Lymphoma‐Associated Chromosomal Breakpoints in Primary Diffuse Large B‐Cell Lymphomas of the Central Nervous System , 2002, Journal of neuropathology and experimental neurology.

[52]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[53]  E. Jordanova,et al.  Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. , 2000, Blood.

[54]  J. Bixby,et al.  Growth Cone Steering by Receptor Tyrosine Phosphatase δ Defines a Distinct Class of Guidance Cue , 2000, Molecular and Cellular Neuroscience.

[55]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[56]  D. Ellison,et al.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. , 1999, Blood.

[57]  R. Siebert,et al.  Primary lymphoma of the central nervous system: just DLBCL or not? , 2009, Blood.

[58]  J. Lilien,et al.  Regulation of Signaling by Protein-Tyrosine Phosphatases: Potential Roles in the Nervous System , 2004, Neurochemical Research.

[59]  J. Bixby,et al.  Growth cone steering by receptor tyrosine phosphatase delta defines a distinct class of guidance cue. , 2000, Molecular and cellular neurosciences.

[60]  E. Rodríguez.  [Malignant lymphomas]. , 1985, Revista de enfermeria.